Objective： To assess the efficacy and safety of do mestic glimepiride (Putangping) in patients with type 2 diabetes mellitus

in comparison with that of glimepiride (Amary1).Methods： After a two-week washout period

56 patients with type 2 diabetes mellitus were randomized into two groups

Group A and Group B

receiving Putangping and Amary1 respectively for 8 weeks.Results： At endpoint

fasting plasma glucose (FPG)

two-hour postprandial plasma glucose(PPG) and HbA1c decreased significantly in both Group A and Group B(P＜0.001). Changes of FPG and HbA1c from baseline to endpoint between the two groups were similar (P＞0.05)

but PPG decreased from baseline to endpoint in Group B exceeded that in Group A (P＜0.05). Fasting and postprandial insulin in both groups increased after the treatment

which was especially obvious for postprandial insulin (P＜0.001).There were no meaningful difference in C-peptide

lipoprotein

hepatic and renal function in the two groups after the trea tment. No hypoglycemia occurred. The incidence of dizziness was similar in both groups .Conclusion： Glimepiride (Petangping) is safe and effective for the treatment of patients with type 2 diabetes mellitus.